An anonymous director reports

NEUROTHERA LABS GRANTED U.S. PATENT FOR CANNABINOID TECHNOLOGY TO OVERCOME ANTIMICROBIAL RESISTANCE SUCH AS MRSA

The United States Patent and Trademark Office has granted a United States patent for Neurothera Labs Inc.'s proprietary combination of antimicrobials and cannabinoids. This patent covers innovative compositions and methods of potentiating antimicrobials, specifically designed to enhance the efficacy of existing antibiotics against resistant bacterial strains.

This patent grant in the United States joins previously granted patents for the same family in the United States, Europe, further strengthening the global intellectual property protection of Neurothera's proprietary antimicrobial-potentiating platform.

The patented technology combines well-established antibiotics-many of which have been on the market for decades -- with cannabinoids such as THC (delta -- tetrahydrocannabinol) and CBD (cannabidiol), and in certain embodiments, N-acylethanolamines like palmitoylethanolamide (PEA). This synergistic approach, which used the company's combination of antimicrobials and cannabinoids, demonstrated in preclinical studies, enhances antimicrobial activity, potentially restoring the effectiveness of antibiotics that are ineffective as monotherapy against resistant Gram-positive pathogens, such as methicillin-resistant staphylococcus aureus (MRSA). When administered in combination with cannabinoids, the platform leverages the extensive long-term safety data of these antibiotics to help minimize risk, potentially offering an effective, safe and affordable therapeutic solution.

Prolonged and widespread antibiotic use has driven the emergence of resistant bacterial strains through genetic mutations and selective pressure. MRSA remains a leading global threat, evading multiple antibiotic classes. According to a comprehensive analysis in The Lancet (September, 2024), MRSA directly caused approximately 130,000 deaths worldwide in 2021 -- more than double the approximately 57,000 deaths in 2019 -- and showed the largest increase in attributable mortality among resistant pathogens. Bacterial antimicrobial resistance (AMR) overall directly caused 1.14 million deaths and was associated with 4.71 million deaths in 2021 worldwide, with a global median methicillin resistance rate of 27.1 per cent in S. aureus bloodstream infections in 2023.

This patent family is based on preclinical studies conducted to evaluate the antimicrobial effects of cannabinoids when combined with antibiotics in well-established, regulatory-compliant models.

The global antibiotics market is projected to reach approximately $58-billion in 2026, according to a report published by Mordor Intelligence entitled "Antibiotics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)," driven by the escalating challenge of antimicrobial resistance. However, with superbugs like MRSA fueling the crisis -- evidenced by a 30-per-cent rise in health-care-acquired infections in the United States over recent years -- the company believes the need for innovative solutions that enhance existing antibiotics' efficacy while improving safety is critical.

The antimicrobial-sparing effect shown in preclinical studies using Neurothera's proprietary combination may eliminate the constant requirements for new antibiotics to combat resistant microbial strains, helping mitigate serious side effects such as resistance development, organ toxicity and gastrointestinal issues, all while capitalizing on the proven safety profiles of long-marketed antibiotics.

According to the World Health Organization, pharmaceutical companies have increasingly shied away from developing new antibiotics due to a combination of prolonged development timelines, high costs and the swift emergence of bacterial resistance, which collectively undermine profitability. The process of bringing a novel antibiotic to market typically spans 10 to 15 years, involving rigorous clinical trials and regulatory hurdles that drive up expenses. Compounding this, bacteria can develop resistance to new antibiotics within just a few years of introduction, leading to restricted usage to preserve efficacy and resulting in limited sales potential compared to chronic disease treatments. As a result, major pharmaceutical firms have largely exited the field, leaving innovation to smaller entities despite the growing threat of antimicrobial resistance.

About Neurothera Labs Inc.

Neurothera Labs is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

We seek Safe Harbor.